Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
folinic acid/vėžys
Nuoroda įrašoma į mainų sritį
Puslapis 1 nuo 118 rezultatus
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Background - Rationale Aflibercept The addition of aflibercept to the standard FOLFIRI regimen as second-line therapy was evaluated in a large phase III study (EFC10262-VELOUR). This combination significantly improved both PFS (4.7 to 6.9 months, HR=0.76; P=<0.001) and OS (12.1 to 13.5 months,
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This will be a multicenter open label randomized phase II study. The study population will include untreated RAS wild-type metastatic colorectal (mCRC) patients with unresectable disease. A total of 136 patients will be enrolled.
All Patients will receive an induction treatment with panitumumab as 1
mFOLFIRNOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of systemic induction of mFOLFIRINOX, followed by HAI floxuridine-dexamethasone administered concurrently with systemic mFOLFIRI.
II. To assess safety of treatment with HAI floxuridine-dexamethasone delivered concurrently with systemic
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Methods: Patients with resectable pancreatic cancer will be treated with oxaliplatin 85 mg/m² IV over 2 hours, irinotecan 150 mg/m² given concurrently with folinic acid 400 mg/m² IV over 90 min, followed by a 46-hour infusion of 5-fluorouracil 2400 mg/m². Slow oral digitalization will be used
FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This trial is an open label, multicenter, randomized phase III trial comparing gemcitabine vs FOLFOX in patients with metastatic pancreatic adenocarcinoma and non-fit for FOLFIRINOX. Adults fulfilling inclusion criteria and non-inclusion criteria will be randomized between a FOLFOX arm and a
Nalirinox Neo-pancreas RAS Mut ctDNA Study
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Background:
The anti-EGFR agents, cetuximab and panitumumab are approved by NICE for the first-line treatment of patients with RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC). However RAS-wt status is not sufficient to guarantee anti-EGFR benefit. Differential tumour expression of the EGFR
Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Colorectal cancer (CRC) is a major cause of morbidity and mortality globally. More than 50% of patients can be expected to develop metastatic disease, and most of these patients will require palliative systemic therapy. The primary goal for patients who present with technically resectable liver
Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Primary objective
- Main objective of phase I: To evaluate the acute toxicity of treatment with FOLFIRINOX 3 - bevacizumab
- Main objective of phase II: To evaluate the efficacy of treatment with FOLFIRINOX 3 - bevacizumab in terms of objective response according to the RECIST criteria.
Secondary
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
This research study is a Phase Ib clinical trial. It will assess the Safety, tolerability, and feasibility of gemcitabine-nab paclitaxel alternating with nal-IRI/5FU/leucovorin (NAPOLI) in de novo resectable and borderline resectable pancreatic cancer.
Subjects must have a newly diagnosed resectable
First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Pancreatic cancer (PC) is the seventh cause from cancer and the fifth cause from cancer-related death in Europe. Nearly as many deaths occur from PC than the number of new cases diagnosed each year, reflecting the poor prognosis typically associated with this disease. PC is insidious in onset and is
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Principal objective:
• To evaluate the survival of patients at 9 months
Secondary objectives:
- Progression-free survival (PFS) (clinical and/or radiological)
- Overall survival (OS)
- Best response rate during treatment according to RECIST 1.1 criteria (according to the investigator and the
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Patients who meet all inclusion and exclusion criteria will be randomized in a 1:1 ratio to one of the following treatment arms (see figure below):
- Arm A (investigational arm): eryaspase in combination with either gemcitabine/Abraxane or irinotecan-based therapy (FOLFIRI [FOLinic
Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) versus Best Supportive Care in third or fourth line treatment of patients with metastatic colorectal cancer.
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
- Dirba 55 kalbomis
- Žolelių gydymas, paremtas mokslu
- Vaistažolių atpažinimas pagal vaizdą
- Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
- Skaitykite mokslines publikacijas, susijusias su jūsų paieška
- Ieškokite vaistinių žolelių pagal jų poveikį
- Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais
